Brokerages Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Price Target at $22.29

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) has been assigned an average recommendation of "Buy" from the nine analysts that are presently covering the stock, Marketbeat.com reports. Eight investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $22.29.

A number of equities analysts have recently commented on ZVRA shares. Cantor Fitzgerald restated an "overweight" rating and set a $25.00 price objective on shares of Zevra Therapeutics in a research note on Wednesday, May 14th. Guggenheim increased their price target on Zevra Therapeutics from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, March 13th. Wall Street Zen upgraded shares of Zevra Therapeutics from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Zevra Therapeutics in a research note on Thursday, March 13th. Finally, JMP Securities set a $18.00 price objective on Zevra Therapeutics in a research note on Wednesday, March 12th.

Zevra Therapeutics Trading Down 2.3%

Shares of NASDAQ:ZVRA traded down $0.20 during mid-day trading on Monday, reaching $8.45. The stock had a trading volume of 494,565 shares, compared to its average volume of 644,735. The firm has a market cap of $462.05 million, a PE ratio of -4.29 and a beta of 1.87. The firm has a 50 day simple moving average of $7.62 and a two-hundred day simple moving average of $8.08. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. Zevra Therapeutics has a twelve month low of $4.20 and a twelve month high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.21) by $0.15. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The business had revenue of $20.40 million for the quarter, compared to the consensus estimate of $16.96 million. During the same period last year, the company posted ($0.40) EPS. On average, research analysts predict that Zevra Therapeutics will post -1.95 EPS for the current fiscal year.

Insider Buying and Selling at Zevra Therapeutics

In other news, Director John B. Bode bought 10,000 shares of the stock in a transaction dated Wednesday, March 19th. The shares were bought at an average price of $7.96 per share, for a total transaction of $79,600.00. Following the completion of the purchase, the director now owns 40,000 shares in the company, valued at approximately $318,400. This trade represents a 33.33% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 2.40% of the company's stock.

Hedge Funds Weigh In On Zevra Therapeutics

Large investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD increased its stake in shares of Zevra Therapeutics by 51.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 20,565 shares of the company's stock worth $172,000 after purchasing an additional 6,966 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Zevra Therapeutics by 50.5% during the fourth quarter. JPMorgan Chase & Co. now owns 27,490 shares of the company's stock worth $229,000 after purchasing an additional 9,225 shares during the period. Raymond James Financial Inc. bought a new position in shares of Zevra Therapeutics during the fourth quarter worth approximately $224,000. Wells Fargo & Company MN increased its stake in shares of Zevra Therapeutics by 65.4% during the fourth quarter. Wells Fargo & Company MN now owns 29,701 shares of the company's stock worth $248,000 after purchasing an additional 11,744 shares during the period. Finally, Rhumbline Advisers increased its stake in shares of Zevra Therapeutics by 18.4% during the fourth quarter. Rhumbline Advisers now owns 68,053 shares of the company's stock worth $568,000 after purchasing an additional 10,573 shares during the period. Institutional investors own 35.03% of the company's stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.